CU Boulder's heart disease drug developer MyoKardia has been picked up by BMS after finishing clinical trials on its lead asset.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Dana-Farber Cancer Institute's cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

The Roche, Novartis and Kraft Group-backed cancer therapy developer raised $182m in an upsized IPO where it floated above its range.

Amgen has invested in Carmot Therapeutics having previously licensed a cancer drug candidate from the company that is currently in phase 2 clinical trials.

The dental services startup boosted its total funding to $73m in a round led by GV, with the cash to support the opening of new clinics.

Johnson & Johnson-backed surgical technology developer Cardiac Dimensions has now raised more than $172m altogether.

McKesson Ventures, Novartis Venture Fund and Merck Global Health Innovation Fund took part in a round for biomarker developer Koneska.

University of Milan spinout Wise is a developer of low-invasive neuromodulation implants for treating pain and neurological disorders.

Sophia Genetics has added Hitachi to its list of shareholders following a $110m series F round that also included returning backer Swisscom.